Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

ATLANTA, Nov. 10 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), a biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2008 financial results and provided an operational update.

Robert McNally, GeoVax's President and CEO, commented, "We are very pleased with the progress we've made during the third quarter of 2008 and for the year so far, as we've taken steps to address both short-term and long-term goals. We made a shipment of the vaccine to the HIV Vaccine Trials Network during October, which is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax and we look forward to HVTN's initiation of the Phase 2a trial later this year. We are also nearing completion of a license with Vivalis S.A., a French biopharmaceutical company, for manufacturing platform technology for the MVA portion of our vaccine that we anticipate will significantly improve the long-term production capabilities for the vaccine."

Financial Results for the Three Months and Nine Months Ended September 30, 2008

The Company recorded a net loss of $722,108 for the three months ended September 30, 2008, compared to $1,165,519 for the same period in 2007. For the nine months ended September 30, 2008, the Company's net loss was $2,688,970 as compared to $3,085,926 in 2007. Net losses for 2008 were partially offset by grant revenues of $1,322,502 and $2,298,571 for the three month and nine month periods, respectively, related to the Company's grant from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development activities. As of September 30, 2008, the Company reported cash balances totaling $2,784,706.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operation
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...4 Sigma-Aldrich Corporat...DAQ OMX conference on Tuesday, December 1st at 1:4...ties may listen via live audio broadcast over the ... a a ldrich.com/ . Users can click the "Webca...a-Aldrich: Sigma-Aldrich is a leading Life Scien...
(Date:11/24/2009)...., Nov. 24 NeurogesX, In...ocused on developing and commercializing novel pai...ny DiTonno, President and Chief Executive Officer,...Jaffray Health Care Conference, to be held Decembe...rk, New York. ,, Mr. DiTonno and Stephen Ghigl...
(Date:11/24/2009)...cy endpoint has been met for patients with advance..., QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AE...e "Company"), a global biopharmaceutical company f...nounced positive efficacy data from a Phase 2 stud...EZS-108 (formerly AN-152), in patients with advanc...
(Date:11/24/2009)...f., Nov. 24 Genomic Heal...dy Scott, Genomic Health,s Executive Chairman, wil...Care Conference in New York City on Tuesday, Decem... live and subsequently archived webcast of the pre... Genomic Health,s website at http://investor.geno...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...erliner Sparkasse in Germany - Large Interest of U...S, Nevada, November 9 Signature Verification,and ...pro presents its Next,Generation Signature Tablet ... Vegas. The Signature experts will showcase their ...leased and highly innovative end-to-end,electronic...
... kill 99.9% of specific common pathogens known to ...ons, including MRSA, DEERFIELD, Ill., Nov. 9 Bax... received 510(k) clearance from the U.S.,Food and ...vated device,(LAD) with VitalShield protective coa...ess IV connector containing an antimicrobial coati...
...Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a b...eveloping and commercializing proprietary product ...ting, today announced that it will release its,thi...lts after the close of,market on Wednesday, Novemb...rence call and live webcast to,discuss the financi...
Other Biology Technology:BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet 2Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology 2Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology 3Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology 4Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results 2
(Date:11/23/2009)...ATINew research presents strong evidence that the ...h outdoor traffic-related pollution and indoor end...ne or the other exposure alone. , Environmenta...i (UC) College of Medicine have shown that childre...articles and indoor endotoxin during early life ar...
(Date:11/23/2009)... study by the Wildlife Conservation Society says t...mp in the Republic of Congopart of the "mother lod...earare becoming increasingly threatened by growing...mmends protection of the swamp forests adjacent to...after recent surveys confirmed that high densities...
(Date:11/23/2009)... Iowa - The only swine vaccine available for the H...infected with the virus. The vaccination marks the...diagnosed with the pandemic flu., Iowa State Uni..., developed the vaccine this summer and has been s...a, Kansas and Illinois for several weeks., The l...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Lives Will Be Lost With Proposed Changes to Mammography Guidelines 61544 1Lives Will Be Lost With Proposed Changes to Mammography Guidelines 61544 2Lives Will Be Lost With Proposed Changes to Mammography Guidelines 61544 3Lives Will Be Lost With Proposed Changes to Mammography Guidelines 61544 4Liquid Tissue 28R 29 Patent Licensed for Amyloidosis Proteomic Assay 6349 1Liquid Tissue 28R 29 Patent Licensed for Amyloidosis Proteomic Assay 6349 2Sinovacs PANFLU 1 28H1N1 29 Regulatory Approval Expanded to Include Geriatric Population 6343 1Sinovacs PANFLU 1 28H1N1 29 Regulatory Approval Expanded to Include Geriatric Population 6343 2
.... Too much of a good thing could be harmful to the...ut silvers ability to kill harmful bacteria and, r...er products containing silver nanoparticles. Now, ... silver nanoparticles also may destroy benign bact...er treatment systems. The study was funded by a gr...
... NEW YORK (APRIL 29, 2008) Bison can repopulate l... years provided a series of conservation and resto...l assessment of this iconic species by the Wildlif...ssment was authored by a diverse group of conserva...ns/First Nations peoples, and appears in the April...
... Fla. -- Ancient farmers were growing sunflowers i...s arrived, according to a team of researchers that...Mary D. Pohl. , In an article published in the jo... Sciences), Pohl and lead author David Lentz of th...firms that farmers began growing sunflowers in Mex...
Other Biology News:Too much technology may be killing beneficial bacteria 2Bison can thrive again, study says 2Sunflower debate ends in Mexico, researchers say 2
Anti-Echovirus LIGHT DIAGNOSTICS Antibody, Unconjugated from CHEMICON
Mouse Anti-JNK, phospho (Thr183 / Thr185) Antibody, Unconjugated from Raybiotech, Inc.
Goat Anti-gamma chain Polyclonal Antibody, HRP Conjugated from Exalpha Biologicals, Inc.
Rabbit Anti-Human ZFP91 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: